Following Sprint Bioscience’s recent rights issue, our certified advisor Redeye has now resumed the company’s surveillance. Read the latest analysis in Swedish here.
Following Sprint Bioscience’s recent rights issue, our certified advisor Redeye has now resumed the company’s surveillance. Read the latest analysis in Swedish here.